Psyence BioMed begins dosing patients in phase IIb psilocybin trial
Go back to Psyence BioMed begins dosing patients in phase IIb psilocybin trial| PACIFIC BOOKER MINERALS, Inc. (NASDAQ: PBM) | Delayed: 2.91 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.91 | 52 Week High | $4.56 | |||
| Open | $2.91 | 52 Week Low | $0.45 | |||
| Day High | $2.91 | P/E | N/A | |||
| Day Low | $2.91 | EPS | $0.00 | |||
| Volume | 865 | |||||
